BG
Bellevue Group Portfolio holdings
AUM
$5.28B
1-Year Est. Return
50.12%
This Fund
S&P 500
1 Year Est. Return
+50.12%
AUM
$5.28B
AUM Growth
+$464M
(+9.6%)
Holding
185
Top Buys
| 1 | +$120M | |
| 2 | +$105M | |
| 3 | +$102M | |
| 4 |
Krystal Biotech
KRYS
|
+$86.1M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$75.6M |
Top Sells
| 1 | +$149M | |
| 2 | +$139M | |
| 3 | +$113M | |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$109M |
| 5 |
argenx
ARGX
|
+$72.3M |
Sector Composition
| 1 | Healthcare | 99.71% |
| 2 | Technology | 0.1% |
| 3 | Consumer Discretionary | 0.05% |
| 4 | Financials | 0.03% |
| 5 | Communication Services | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Recursion Pharmaceuticals
RXRX
$1.81B
| $20.1K | ﹤0.01% |
4,921
-593
|
|
||
177
Agios Pharmaceuticals
AGIO
$1.66B
| – | – |
-3,714,736
|
|
||
|
AKRO
178
DELISTED
Akero Therapeutics
AKRO
| – | – |
-2,389,314
|
|
||
179
Baxter International
BAX
$9.51B
| – | – |
-68,084
|
|
||
180
Biohaven
BHVN
$1.41B
| – | – |
-2,802,853
|
|
||
181
Baidu
BIDU
$40.1B
| – | – |
-2,000
|
|
||
182
Hologic
HOLX
$16.8B
| – | – |
-247,886
|
|
||
183
MacroGenics
MGNX
$115M
| – | – |
-9,919,992
|
|
||
184
MoonLake Immunotherapeutics
MLTX
$1.23B
| – | – |
-35,052
|
|
||
|
MRUS
185
DELISTED
Merus
MRUS
| – | – |
-825
|
|